浩欧博收盘下跌2.70%，滚动市盈率169.77倍，总市值58.80亿元

Group 1 - The core business of the company is the research, production, and sales of in vitro diagnostic reagents, with major products including allergy reagents and autoimmune reagents [2] - As of the latest report, the company has obtained 226 product registration certificates and holds 57 patents, indicating a strong position in innovation and technology [2] - The company has received multiple honors, including being recognized as a high-tech enterprise and receiving various awards for innovation and creditworthiness [2] Group 2 - As of June 3, the company's stock closed at 93.24 yuan, down 2.70%, with a rolling PE ratio of 169.77 times, significantly higher than the industry average of 50.80 times [1][3] - The total market capitalization of the company is 5.88 billion yuan, ranking 113th in the industry based on PE ratio [1][3] - The latest quarterly report for Q1 2025 shows a revenue of 77.61 million yuan, a year-on-year decrease of 9.33%, and a net profit of 1.64 million yuan, down 56.97% year-on-year, with a gross margin of 57.98% [2]